The Pfizer partnership validates Novavax's Matrix-M technology and provides significant future revenue potential. Traders should monitor milestone achievements and royalty streams. The strong revenue growth and improved profitability suggest a turnaround, but the decline in Nuvaxovid sales and cash balance warrant caution. The $330 million credit facility strengthens the balance sheet for future R&D investments.
Price Chart
Executive Summary
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $1.12 billion for the full year, driven by Sanofi milestones and licensing revenue. The company also announced a major non-exclusive license agreement with Pfizer for its Matrix-M adjuvant technology, receiving a $30 million upfront payment and potential for up to $500 million in milestones. Despite a cash balance decline to $751 million, Novavax secured a $330 million credit facility and guided to $230-$270 million in adjusted revenue for 2026.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $147 million (+67% YoY)
- Full year 2025 revenue: $1.123 billion (+65% YoY)
- Net income: $18 million in Q4 2025 vs. $81 million loss in Q4 2024
- Pfizer agreement: $30 million upfront, up to $500 million in milestones, and high-mid-single digit royalties
- Sanofi partnership: $225 million in milestones earned in 2025
- Cash balance: $751 million as of Dec 31, 2025
- 2026 revenue guidance: $230-$270 million (adjusted total revenue)
Financial Impact
Revenue increased by $589 million YoY to $1.123 billion in 2025, with Q4 revenue up $59 million to $147 million. Net income improved by $99 million YoY in Q4.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Nuvaxovid Sales | $625.0M | — |
| Sanofi | $386.0M | -16.0% |
| Licensing, Royalties and Other Revenue | $438.4M | -7.0% |
Risk Factors
- Decline in Nuvaxovid product sales from $625 million in 2025 to $35-$45 million expected in 2026
- Cash balance decreased from $938 million in 2024 to $751 million in 2025
- Future revenue dependent on partner performance (Sanofi, Pfizer) and milestone achievement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001000694-26-000011 |
| Document: nvax-20260226.htm | 0001000694-26-000011 |
| Document: 0001000694-26-000011-index-headers.html | 0001000694-26-000011 |
| Document: 0001000694-26-000011-index.html | 0001000694-26-000011 |
| Document: 0001000694-26-000011.txt | 0001000694-26-000011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $7.74 $10.34 | ▲ +33.59% | ▲ +32.99% | $10.46 (+35.14%) |
May 6, 2026 21w ago | 8-K | $9.36 $10.20 | ▲ +8.97% | ▲ +6.19% | $10.46 (+11.75%) |
Apr 27, 2026 22w ago | DEFA14A | $8.07 $10.46 | ▲ +29.62% | ▲ +24.66% | $10.46 (+29.62%) |
Feb 26, 2026 31w ago | 8-K | $11.19 $8.95 | ▼ −20.02% | ▼ −13.62% | $10.46 (−6.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access